Drug intelligence / Profile preview

KangYanJingFang

Development stage: Unknown
Lead developer: Longhua Hospital Shanghai University of Traditional Chinese Medicine
Administration: Oral

Overview

KangYanJingFang is a Traditional Chinese Medicine (TCM) herbal formula developed by Longhua Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is primarily investigated as an adjuvant therapy for patients with stage II high-risk or stage III colorectal cancer following radical surgery. The formula is administered in combination with standard chemotherapy regimens, such as CapeOx (capecitabine and oxaliplatin) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin). The clinical objective of KangYanJingFang is to improve the chemotherapy completion rate, alleviate cancer-related fatigue, and enhance the overall quality of life by mitigating the systemic toxicities associated with cytotoxic chemotherapy.

Other names: Kang Yan Jing Fang

Beyond the preview

Go deeper on KangYanJingFang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KangYanJingFang.

Explore the full profile